Recently, several teams utilised a cell‐based vascular endothelial growth factor (VEGF) cmRNA delivery platform to enhance therapeutic applications in limb ischemia, myocardial infarction, bone defects, and fat grafting [22, 23, 24, 25]. This evidence concerns the gene VEGFA and myocardial infarction.